Search research articles
Contact Us
Filters
Showing results (301-310 of 692) with videos related to
Page
of 70
Sort By:
International Journal of Cancer
|
November 14, 1997
Mechanisms for high methoxymorpholino doxorubicin cytotoxicity in doxorubicin-resistant tumor cell lines
M Bakker, J Renes, A Groenhuijzen, et al.
Journal for Immunotherapy of Cancer
|
July 23, 2025
Response to: Comment on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study' by Zhu
Michiel M Smeenk, Vincent van der Noort, Jeroen J M A Hendrikx, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
June 4, 2015
Differences between pulmonologists, thoracic surgeons and radiation oncologists in deciding on the treatment of stage I non-small cell lung cancer: A binary choice experiment
Wendy Hopmans, Laura Zwaan, Suresh Senan, et al.
Thorax
|
January 4, 2003
Prospective use of serial questionnaires to evaluate the therapeutic efficacy of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in suspected lung cancer
G J Herder, H Van Tinteren, E F Comans, et al.
Lung Cancer (Amsterdam, Netherlands)
|
October 15, 2011
SUVmax during 18FDG-PET scanning in small cell lung cancer: similar information as in non-small cell lung cancer?
C van der Leest, E F Smit, J Baas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2002
Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460
Cynthia Huisman, Carlos G Ferreira, Linda E Bröker, et al.
Inflammatory Bowel Diseases
|
January 4, 2013
Production and cellular source of interleukin-8 in ulcerative colitis
D W Hommes, S A Radema, J Jansen, et al.
Journal for Immunotherapy of Cancer
|
July 23, 2025
Response to: Correspondence on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer-a real-world, retrospective bicenter cohort study' by Wang
Michiel M Smeenk, Vincent van der Noort, Jeroen J M A Hendrikx, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 12, 2001
Single-agent gemcitabine in patients with resistant small-cell lung cancer
I van der Lee, E F Smit, J W van Putten, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology
|
October 24, 2007
The multicomponent phytopharmaceutical SKI306X inhibits in vitro cartilage degradation and the production of inflammatory mediators
A Hartog, S Hougee, J Faber, et al.
Page
of 70
Search research articles
Search
Showing results (301-310 of 692) with videos related to
Sort By:
Page
of 70
International Journal of Cancer
|
November 14, 1997
Mechanisms for high methoxymorpholino doxorubicin cytotoxicity in doxorubicin-resistant tumor cell lines
M Bakker, J Renes, A Groenhuijzen, et al.
Journal for Immunotherapy of Cancer
|
July 23, 2025
Response to: Comment on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study' by Zhu
Michiel M Smeenk, Vincent van der Noort, Jeroen J M A Hendrikx, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
June 4, 2015
Differences between pulmonologists, thoracic surgeons and radiation oncologists in deciding on the treatment of stage I non-small cell lung cancer: A binary choice experiment
Wendy Hopmans, Laura Zwaan, Suresh Senan, et al.
Thorax
|
January 4, 2003
Prospective use of serial questionnaires to evaluate the therapeutic efficacy of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in suspected lung cancer
G J Herder, H Van Tinteren, E F Comans, et al.
Lung Cancer (Amsterdam, Netherlands)
|
October 15, 2011
SUVmax during 18FDG-PET scanning in small cell lung cancer: similar information as in non-small cell lung cancer?
C van der Leest, E F Smit, J Baas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2002
Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460
Cynthia Huisman, Carlos G Ferreira, Linda E Bröker, et al.
Inflammatory Bowel Diseases
|
January 4, 2013
Production and cellular source of interleukin-8 in ulcerative colitis
D W Hommes, S A Radema, J Jansen, et al.
Journal for Immunotherapy of Cancer
|
July 23, 2025
Response to: Correspondence on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer-a real-world, retrospective bicenter cohort study' by Wang
Michiel M Smeenk, Vincent van der Noort, Jeroen J M A Hendrikx, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 12, 2001
Single-agent gemcitabine in patients with resistant small-cell lung cancer
I van der Lee, E F Smit, J W van Putten, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology
|
October 24, 2007
The multicomponent phytopharmaceutical SKI306X inhibits in vitro cartilage degradation and the production of inflammatory mediators
A Hartog, S Hougee, J Faber, et al.
Page
of 70